In July 2010 Verisante Technology (OTCPK:VRSEF) entered a licensing agreement with British Columbia's BC Cancer Agency for use of their cancer detection technology in order to accelerate development of their cancer detection device program. Initial commercialization of the device is focused on the detection of skin cancer, with extensions of the product expected to follow for the detection of other cancers, including lung, gastro-intestinal and cervical.
Skin cancer is a relatively common disease, the incidence of which is on the rise. Since melanoma is progressive and usually fatal in later stages, early detection and removal of cancerous skin lesions is critical to improve patient outcomes. Verisante's patented Aura device has been designed to do just that.
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|